Home

Merck

Pfizer Diagnoses Fido, Too

Fri, 12/31/2010 - 15:46 by Brian Orelli

Pfizer (NYSE: PFE) is jumping into the diagnostic business with all four paws. The company announced yesterday that it's purchasing Synbiotics to gain access to its veterinary immunodiagnostics business.

How Cheap Is Merck's Stock by the Numbers?

Sun, 12/12/2010 - 10:14 by Anand Chokkavelu

 Numbers can lie -- yet they're the best first step in determining whether a stock is a buy. In this series, we use some carefully chosen metrics to size up a stock's true value based on the following clues:

 

How Cheap Is Celgene's Stock by the Numbers?

Fri, 12/10/2010 - 11:01 by Anand Chokkavelu

 Numbers can lie -- but they're the best first step in determining whether a stock is a buy. In this series, we use some carefully chosen metrics to size up a stock's true value based on the following clues:

 

5-Star Stocks Poised to Pop: Novartis

Mon, 12/06/2010 - 22:57 by Brian D. Pacampara

 Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, Swiss pharmaceutical giant Novartis (NYSE:NVS) has earned a respected five-star ranking.

 

An Ounce of Prevention Gets Shot Down

Fri, 12/03/2010 - 13:57 by Brian Orelli

An ounce of prevention is worth a pound of cure. It's also worth big bucks.

RNAi Is On Sale

Wed, 12/01/2010 - 11:27 by Brian Orelli

 After bashing RNAi over the past few years -- see here and here for examples -- I think the pioneering technology is looking a little more appetizing. The field has advanced, but more importantly, the prices have come down. A lot.

 

Is Eli Lilly the Perfect Stock?

Tue, 11/30/2010 - 12:33 by Dan Caplinger

 Everyone would love to find the perfect stock. But will you ever really find a stock that gives you everythingyou could possibly want?  One thing's for sure: If you don't look, you'll never find truly great investments. So let's first take a look at what you'd want to see from a perfect stock, and then decide if Eli Lilly(NYSE: LLY) fits the bill.

 

Fatter Wallet? Maybe Some Other Day.

Sat, 10/30/2010 - 10:20 by Brian Orelli

 Are you an optimist? "In the [complete response letter], no new clinical studies were requested."

 

The One Thing to Know About Merck

Wed, 09/08/2010 - 10:24 by Jeremy Phillips

I know it sounds ludicrous, but investors often overlook the people in charge of protecting their investments. The idea of gauging a company's leadership plays second-fiddle to other categories of analysis. However, at Fool.com we believe careful study of effective leadership is one of the most important areas of evaluating long-term winning investments.

3 Lifeboat Stocks

Wed, 08/04/2010 - 12:41 by Brian Orelli

With the market down about 10% over the past three months, and concerns over Europe's debt crisis, China's slowing economy, and the BP spill still in the forefront of news, investors have every right to be concerned. To survive this downturn, you should be asking yourself, "Are my stocks lifeboats, ready to save me, or wreckage sending me to the bottom?

It's Hard to Get Excited About 92% Revenue Growth

Sat, 07/31/2010 - 12:34 by Brian Orelli

Merck (NYSE: MRK) beat analysts' earnings expectations in the second quarter, but it's hard to get excited about decreasing costs and lower taxes especially considering the risks the drugmaker faces.

5-Star Stocks Poised to Pop: Endo Pharmaceuticals

Thu, 07/29/2010 - 02:06 by Brian D. Pacampara

Based on the aggregated intelligence of 165,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug companyEndo Pharmaceuticals Holdings (Nasdaq: ENDP) has earned a covetedfive-star ranking.